Leede Jones Gable downgraded Medical Facilities (TSX:DR) to “hold” from “buy” and lowered its price target to $9.25 (Canadian) from $12, citing solid top-line data in the third quarter of 2022, offset by cost pressures...
Leede Jones Gable initiated coverage of ProMIS Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents (Canadian). The stock closed at 11 cents on May 10. The firm’s lead preclinical...
Leede Jones Gable initiated coverage of Perimeter Medical Imaging (TSXV:PINK) with a “speculative buy” rating and price target of $6.75 (Canadian). The stock closed at $4.30 on March 26. The firm’s lead medical device...
Leede Jones Gable initiated coverage of Cardiol Therapeutics (TSX:CRDL) with a “speculative buy” rating and price target of $12.50 (Canadian). The stock closed at $4.51 on March 24. Analyst Doug Loe, Ph.D., writes that...
Leede Jones Gable launched coverage of Profound Medical (TSX:PRN) with a “buy” rating and price target of $36.50 (Canadian). The stock gained $2.96, or 13%, to close at $26.18 on Dec. 21. The firm’s flagship device...
Leede Jones Gable initiated coverage of Protech Home Medical (TSXV:PTQ) with a “buy” rating and price target of $3.25. The stock closed at $1.47 on Dec. 18. Protech is a durable medical equipment (DME) and home...
Leede Jones Gable initiated coverage of IntelGenx Technologies (TSXV:IGX) with a “speculative buy” rating and price target of $1.00 (Canadian). The stock closed at 37 cents on Dec. 15. IntelGenx is a thin-film...
Leede Jones Gable launched coverage of IMV (TSX:IMV) with a “speculative buy” and price target of $10.50 (Canadian). The stock closed at $4.03 on Dec. 15. IMV’s flagship technology platform is the lipid-based water-free...
Leede Jones Gable initiated coverage of Liminal BioSciences (NASDAQ:LMNL) with a “hold” rating and $4 price target. The stock closed at $4.20 on Dec. 15. Liminal is a plasma products and anti-fibrotic small molecule...
Leede Jones Gable launched coverage of Oncolytics Biotech (TSX:ONC) with a “speculative buy” rating and $8.50 (Canadian) price target. The stock closed at $3.07 on Dec. 15. Oncolytics is a cancer-focused virus-based...